Want to see HK:1801 full AI Analyst Report?
1801 Stock Chart & Stats
HK$100.10
-HK$0.60(-0.67%)
At close: 4:00 PM EDT
HK$100.10
-HK$0.60(-0.67%)
Day’s Range― - ―
52-Week RangeHK$69.55 - HK$112.70
Previous CloseN/A
Volume6.80M
Average Volume (3M)13.10M
Market Cap
HK$167.33B
Enterprise ValueHK$122.92K
Total Cash (Recent Filing)HK$20.00B
Total Debt (Recent Filing)HK$2.32B
Price to Earnings (P/E)118.4
Beta0.74
Next Earnings
Mar 31, 2027EPS Estimate
1.33Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.71
Shares Outstanding1,744,845,100
10 Day Avg. Volume10,200,052
30 Day Avg. Volume13,102,299
Financial Highlights & Ratios
PEG Ratio-0.15
Price to Book (P/B)6.12
Price to Sales (P/S)9.09
P/FCF Ratio12.72
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
HK$132.80Price Target Upside32.67% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering22
EPS Forecast (FY)1.37
Revenue Forecast (FY)HK$18.67B
Bulls Say, Bears Say
Bulls Say
Revenue Growth And Gross ProfitabilityThe 2025 revenue increase, return to profitability, and stronger gross margin indicate improving commercial traction and product economics. If maintained, this combination can support reinvestment in the pipeline, strengthen operating leverage, and improve the company’s ability to fund growth internally.
Strong 2025 Cash GenerationThe sharp improvement in operating and free cash flow gives Innovent greater capacity to finance clinical development, manufacturing, and commercialization without relying as heavily on external capital. Sustained cash conversion would materially strengthen strategic flexibility across its drug lifecycle.
Expanded Jaypirca ApprovalThe expanded regulatory label broadens Jaypirca’s addressable patient population and supports use across the CLL/SLL treatment continuum. The approval is backed by Phase 3 evidence, creating a durable commercial opportunity for Innovent’s marketed oncology portfolio.
Bears Say
Profitability Durability Remains UnprovenAlthough 2025 marked a meaningful profit inflection, the preceding multi-year loss record shows that positive earnings have not yet been demonstrated consistently. Continued execution across commercialization and development will be necessary before the recent improvement can be viewed as durable.
Historically Inconsistent Cash FlowThe strong 2025 cash result is not yet supported by a long history of consistent cash generation. Earlier negative operating and free cash flow suggests that future liquidity and internal funding capacity could remain sensitive to development spending, working-capital movements, or operating volatility.
Modest Net Profitability And ReturnsHigh gross profitability has not yet translated into robust bottom-line returns, with net margin and return measures still modest. This indicates that operating expenses and the broader investment burden continue to absorb much of the product economics, limiting earnings resilience.
Innovent Biologics News
1801 FAQ
What was Innovent Biologics’s price range in the past 12 months?
Innovent Biologics lowest stock price was HK$69.55 and its highest was HK$112.70 in the past 12 months.
What is Innovent Biologics’s market cap?
Innovent Biologics’s market cap is HK$167.33B.
When is Innovent Biologics’s upcoming earnings report date?
Innovent Biologics’s upcoming earnings report date is Mar 31, 2027 which is in 181 days.
How were Innovent Biologics’s earnings last quarter?
Innovent Biologics released its earnings results on Aug 25, 2026. The company reported HK$0.818 earnings per share for the quarter, beating the consensus estimate of HK$0.549 by HK$0.269.
Is Innovent Biologics overvalued?
According to Wall Street analysts Innovent Biologics’s price is currently Undervalued.
Does Innovent Biologics pay dividends?
Innovent Biologics does not currently pay dividends.
What is Innovent Biologics’s EPS estimate?
Innovent Biologics’s EPS estimate is 1.33.
How many shares outstanding does Innovent Biologics have?
Innovent Biologics has 1,744,845,100 shares outstanding.
What happened to Innovent Biologics’s price movement after its last earnings report?
Innovent Biologics reported an EPS of HK$0.818 in its last earnings report, beating expectations of HK$0.549. Following the earnings report the stock price went up 0.603%.
Which hedge fund is a major shareholder of Innovent Biologics?
Currently, no hedge funds are holding shares in HK:1801
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Innovent Biologics Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
HK$132.80 (32.67% Upside)
HK$132.80 (32.67% Upside)
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
9.06%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
86.27%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Innovent Biologics
Innovent Biologics, Inc., established in 2011 and headquartered in Suzhou, People's Republic of China, functions as a leading biopharmaceutical enterprise. The company is dedicated to the comprehensive lifecycle of antibody drug candidates, encompassing their discovery, development, and eventual manufacturing. Its therapeutic focus spans critical areas such as oncology, ophthalmology, immunology, and metabolic diseases. A key product in its portfolio is Tyvyt (sintilimab), an anti-PD-1 monoclonal antibody utilized in the treatment of various cancers, including Hodgkin's lymphoma and esophageal carcinoma. Innovent's commercialized offerings also include Byvasda, employed for several malignant tumors; Halpryza, which addresses non-Hodgkin's lymphoma, chronic lymphocytic leukemia, and Wegener's granulomatosis; Pemazyre, indicated for adults with locally advanced or metastatic cholangiocarcinoma; Olverembatinib, designed for adult patients facing conditions related to tyrosine kinase inhibitors; and Cyramza, approved for four distinct cancer types. The company's robust pipeline features a range of investigational therapies, such as IBI-301, a rituximab biosimilar for non-Hodgkin's lymphoma; IBI-302, a bispecific antibody fusion protein aimed at ocular fundus disease; IBI-306, a human monoclonal antibody targeting hypercholesterolemia; and IBI-310, a recombinant human anti-CTLA-4 monoclonal antibody for liver and renal cell carcinoma. Further developmental assets include IBI-188, an anti-CD47 monoclonal antibody for advanced hematological and solid tumors; IBI-326, a fully human BCMA-CAR T-cell therapy for adults with relapsed or refractory multiple myeloma; IBI-376 for recurrent or refractory follicular lymphoma; and IBI-112 for psoriasis. Beyond drug creation, Innovent Biologics is also involved in distributing pharmaceutical products and provides expert consultation along with research and development services. The company maintains key strategic alliances with various partners, including NeoCura Bio-Medical Technology Co. Ltd., Roche Group, Ascentage Pharma Group International, Eli Lilly and Company, and Bolt Biotherapeutics, Inc.
1801 Stock 12 Month Forecast
Average Price Target
HK$132.80
▲(32.67% Upside)
Technical Analysis
3SBio
―
Akeso, Inc.
―
RemeGen Co. Ltd. Class H
―
Shanghai Junshi Biosciences Co., Ltd. Class H
―
Shanghai Henlius Biotech, Inc. Class H
―